Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colistin + levofloxacin vs colistin + meropenem for ventilator-associated pneumonia due to Acinetobacter
IRCT20150721023282N17Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jun 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in ventilator-associated pneumonia (VAP) and Acinetobacter infection comparing Colistin + levofloxacin with Colistin + meropenem (2 arms). Started Jun 2021; status: completed.
02
Drugs
colistinlevofloxacinmeropenem
03
Conditions
ventilator-associated pneumonia (VAP)Acinetobacter infection
Beyond the preview
Go deeper on IRCT20150721023282N17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150721023282N17.